Royalty Pharma plc (RPRX): Cash & Equivalents
$618.70M
As of 2025-12-31
$811.99M
As of 2026-06-30
-28.8%
3-year compound annual growth
-9.3%
5-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $618.70M | -33.4% | 2026-02-11, Balance as of period end |
| 2024-12-31 | $929.03M | +94.8% | 2026-02-11, Balance as of period end |
| 2023-12-31 | $477.01M | -72.1% | 2025-02-12, Balance as of period end |
| 2022-12-31 | $1.71B | +11.0% | 2024-02-15, Balance as of period end |
| 2021-12-31 | $1.54B | +52.8% | 2023-02-15, Balance as of period end |
| 2020-12-31 | $1.01B | +309.7% | 2022-02-15, Balance as of period end |
| 2019-12-31 | $246.20M | n/a | 2021-02-24, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Royalty Pharma plc (RPRX) | 2025-12-31 | $618.70M | -33.4% |
| Sarepta Therapeutics, Inc. (SRPT) | 2025-12-31 | $801.28M | -27.4% |
| Amneal Pharmaceuticals, Inc. (AMRX) | 2025-12-31 | $282.03M | +155.1% |
| United Therapeutics Corp (UTHR) | 2025-12-31 | $1.56B | -8.3% |
| BioMarin Pharmaceutical Inc (BMRN) | 2025-12-31 | $1.31B | +39.1% |
| PTC Therapeutics, Inc. (PTCT) | 2025-12-31 | $984.65M | +26.3% |
| Alnylam Pharmaceuticals, Inc. (ALNY) | 2025-12-31 | $1.66B | +71.5% |
| Phibro Animal Health Corp (PAHC) | 2026-06-30 | $61.42M | -9.7% |
| Alkermes plc. (ALKS) | 2025-12-31 | $388.57M | +33.5% |
Compare RPRX, SRPT, AMRX, UTHR side by side · Screen every company in Pharmaceutical Preparations ↗